Gulisa Turashvili

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/538621/publications.pdf

Version: 2024-02-01

92 papers	16,671 citations	168829 31 h-index	53065 89 g-index
98 all docs	98 docs citations	98 times ranked	27234 citing authors

#	Article	IF	Citations
1	Lynch Syndrome Screening of Women with Endometrial Cancer: Feasibility and Outcomes in a Community Program. Journal of Obstetrics and Gynaecology Canada, 2022, 44, 142-147.	0.3	1
2	EPM2AIP1 Immunohistochemistry Can Be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer. American Journal of Surgical Pathology, 2022, 46, 376-382.	2.1	5
3	Uterine Sarcoma With FGFR1-TACC1 Gene Fusion: A Case Report and Review of the Literature. International Journal of Gynecological Pathology, 2022, 41, 588-592.	0.9	1
4	â€œGame Changerâ€• Health Professionalsâ€™ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management. Oncologist, 2022, 27, e393-e401.	1.9	5
5	Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. Current Oncology, 2022, 29, 2599-2616.	0.9	5
6	Endometrial Stromal Sarcomas With BCOR Internal Tandem Duplication and Variant BCOR/BCORL1 Rearrangements Resemble High-grade Endometrial Stromal Sarcomas With Recurrent CDK4 Pathway Alterations and MDM2 Amplifications. American Journal of Surgical Pathology, 2022, 46, 1142-1152.	2.1	10
7	Recurrent KAT6B/A::KANSL1 Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma. American Journal of Surgical Pathology, 2022, 46, 1298-1308.	2.1	4
8	A Survey of Breast Pathologistsâ€™ Practice in Staging Multiple Foci of Invasive Carcinoma. Clinical Breast Cancer, 2021, 21, e506-e511.	1.1	1
9	Pathology of IgG4-related sclerosing mastitis. Journal of Clinical Pathology, 2021, 74, 475-482.	1.0	7
10	Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. JAMA Surgery, 2021, 156, 157.	2.2	118
11	p53 immunohistochemical analysis of fusionâ€positive uterine sarcomas. Histopathology, 2021, 78, 805-813.	1.6	17
12	HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study. Breast Cancer Research and Treatment, 2021, 186, 99-105.	1.1	2
13	SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. International Journal of Gynecological Pathology, 2021, 40, 487-494.	0.9	7
14	MLH1 epimutation is a rare mechanism for Lynch syndrome: A case report and review of the literature. Genes Chromosomes and Cancer, 2021, 60, 635-639.	1.5	2
15	<scp>PLAG1</scp>â€rearrangement in a uterine leiomyosarcoma with myxoid stroma and heterologous differentiation. Genes Chromosomes and Cancer, 2021, 60, 713-717.	1.5	13
16	BCOR Internal Tandem Duplication Associated Uterine Sarcoma. International Journal of Gynecological Pathology, 2021, Publish Ahead of Print, .	0.9	3
17	Whatâ€™s new in gynecologic pathology 2021: ovary and fallopian tube. Journal of Pathology and Translational Medicine, 2021, 55, 366-367.	0.4	2
18	Solid Papillary Carcinoma and Encapsulated Papillary Carcinoma of the Breast: Clinical-Pathologic Features and Basement Membrane Studies of 50 Cases. Pathobiology, 2021, 88, 359-373.	1.9	7

#	Article	IF	Citations
19	NTRK-rearranged Cervical Sarcoma: Expanding the Clinicopathologic Spectrum. International Journal of Gynecological Pathology, 2021, 40, 73-77.	0.9	21
20	Protracted clinical course of an AFF1 fusion positive uterine smooth muscle tumor causing diagnostic confusion over a course of 15Âyears. Gynecologic Oncology Reports, 2021, 38, 100890.	0.3	0
21	Androgenetic/Biparental Mosaic/Chimeric Conceptions With a Molar Component: A Diagnostic and Clinical Challenge. International Journal of Gynecological Pathology, 2021, 40, 510-517.	0.9	5
22	Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases. International Journal of Gynecological Pathology, 2020, 39, 72-78.	0.9	12
23	Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. Cancers, 2020, 12, 3468.	1.7	12
24	Gene fusions characterize a subset of uterine cellular leiomyomas. Genes Chromosomes and Cancer, 2020, 59, 688-696.	1.5	8
25	Pathology of Hereditary Breast and Ovarian Cancer. Frontiers in Oncology, 2020, 10, 531790.	1.3	30
26	Editorial: Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment. Frontiers in Oncology, 2020, 10, 618369.	1.3	2
27	Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects. Nature Cancer, 2020, 1, 518-532.	5.7	11
28	High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. Modern Pathology, 2020, 33, 1861-1870.	2.9	26
29	Multigene testing in breast cancer: What have we learned from the 21â€gene recurrence score assay?. Breast Journal, 2020, 26, 1199-1207.	0.4	8
30	ADNP (Activity Dependent Neuroprotector Homeobox): A novel oncogene driving poor prognosis in high-grade serous carcinoma. EBioMedicine, 2020, 51, 102589.	2.7	2
31	Cystic neutrophilic granulomatous mastitis: an update. Journal of Clinical Pathology, 2020, 73, 445-453.	1.0	47
32	Classic IgG4â€related sclerosing mastitis is not so classic. Breast Journal, 2020, 26, 1245-1248.	0.4	7
33	Secondary Involvement of the Uterine Cervix by Nongynecologic Neoplasms. American Journal of Surgical Pathology, 2020, 44, 1699-1711.	2.1	2
34	Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens. International Journal of Gynecological Pathology, 2019, 38, 263-275.	0.9	18
35	Cervical Glandular Neoplasia. Surgical Pathology Clinics, 2019, 12, 281-313.	0.7	9
36	Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer. Breast Cancer Research, 2019, 21, 12.	2.2	36

#	Article	IF	Citations
37	PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features. American Journal of Surgical Pathology, 2019, 43, 810-818.	2.1	28
38	Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology, 2019, 152, 38-45.	0.6	18
39	Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. Npj Breast Cancer, 2018, 4, 5.	2.3	32
40	The 21-Gene Recurrence Score in Male Breast Cancer. Annals of Surgical Oncology, 2018, 25, 1530-1535.	0.7	14
41	<scp>BRAF^V</scp>^{600E} mutations and immunohistochemical expression of <scp>VE</scp>1 protein in lowâ€grade serous neoplasms of the ovary. Histopathology, 2018, 73, 438-443.	1.6	22
42	Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors. Gynecologic Oncology Reports, 2018, 24, 94-98.	0.3	6
43	Novel prognostic and predictive microRNA targets for tripleâ€negative breast cancer. FASEB Journal, 2018, 32, 5937-5954.	0.2	57
44	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. BMC Cancer, 2018, 18, 42.	1.1	9
45	DNA methylation-based classifier for diagnosis of endometrial cancer.. Journal of Clinical Oncology, 2018, 36, e17570-e17570.	0.8	0
46	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. Breast Cancer Research and Treatment, 2017, 165, 65-76.	1.1	28
47	Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation. Gynecologic Oncology Reports, 2017, 22, 9-12.	0.3	0
48	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 166, 69-76.	1.1	31
49	Tumor Heterogeneity in Breast Cancer. Frontiers in Medicine, 2017, 4, 227.	1.2	379
50	A 64â€Yearâ€Old Male with Leg Pain. Brain Pathology, 2016, 26, 677-678.	2.1	0
51	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature Communications, 2016, 7, 11479.	5.8	1,221
52	Bilateral adrenal histoplasmosis in a man with chronic alcoholism. Journal of Microbiology, Immunology and Infection, 2016, 49, 797-798.	1.5	3
53	Human Papillomavirus-Related Ovarian Metastasis With Endocervical Adenocarcinoma. Journal of Lower Genital Tract Disease, 2015, 19, e60-e63.	0.9	9
54	Mucinous metaplasia of the endometrium: Current concepts. Gynecologic Oncology, 2015, 136, 389-393.	0.6	10

#	Article	IF	Citations
55	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Molecular Oncology, 2015, 9, 115-127.	2.1	38
56	First fatal case of systemic suppurative/necrotizing granulomatous disease following etanercept therapy for psoriasis. Journal of Dermatological Treatment, 2015, 26, 124-127.	1.1	3
57	A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. British Journal of Cancer, 2015, 112, 1215-1222.	2.9	54
58	In Vivo Radioimaging of Bradykinin Receptor B1, a Widely Overexpressed Molecule in Human Cancer. Cancer Research, 2015, 75, 387-393.	0.4	48
59	Fatal Esophageal Squamous Cell Carcinoma at a Young Age as a Complication of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. AACE Clinical Case Reports, 2015, 1, e240-e244.	0.4	0
60	Does age influence the intrinsic biology of breast cancer?. Journal of Clinical Oncology, 2015, 33, 11044-11044.	0.8	0
61	The Velvet Myocardium: Potential Harbinger of Death in Acute Myocarditis?. Canadian Journal of Cardiology, 2013, 29, 1742.e25-1742.e27.	0.8	1
62	The shaping and functional consequences of the microRNA landscape in breast cancer. Nature, 2013, 497, 378-382.	13.7	370
63	TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells. Molecular Cancer Research, 2013, 11, 1179-1192.	1.5	31
64	Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling. Science Translational Medicine, 2012, 4, 157ra143.	5.8	356
65	Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Research, 2012, 22, 1995-2007.	2.4	237
66	JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data. Bioinformatics, 2012, 28, 907-913.	1.8	159
67	The landscape of cancer genes and mutational processes in breast cancer. Nature, 2012, 486, 400-404.	13.7	1,535
68	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 2012, 486, 346-352.	13.7	4,708
69	The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 2012, 486, 395-399.	13.7	1,778
70	Nucleic acid quantity and quality from paraffin blocks: Defining optimal fixation, processing and DNA/RNA extraction techniques. Experimental and Molecular Pathology, 2012, 92, 33-43.	0.9	100
71	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Research and Treatment, 2012, 132, 131-142.	1.1	117
72	Mll5 Is Required for Normal Spermatogenesis. PLoS ONE, 2011, 6, e27127.	1.1	50

#	Article	IF	Citations
73	The testosterone-dependent and independent transcriptional networks in the hypothalamus of Gpr54 and Kiss1 knockout male mice are not fully equivalent. BMC Genomics, 2011, 12, 209.	1.2	13
74	P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Modern Pathology, 2011, 24, 64-81.	2.9	60
75	PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance. Cancer Discovery, 2011, 1, 326-337.	7.7	53
76	BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. British Journal of Cancer, 2010, 103, 668-675.	2.9	259
77	ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543.	13.9	1,460
78	Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situhybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer, 2009, 9, 165.	1.1	68
79	Columnar cell lesions, mammographic density and breast cancer risk. Breast Cancer Research and Treatment, 2009, 115, 561-571.	1.1	22
80	A Case of Osteoclast-like Giant Cell Tumor of the Pancreas Associated with Borderline Mucinous Cystic Neoplasm. Pathology and Oncology Research, 2009, 15, 129-131.	0.9	12
81	Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature, 2009, 461, 809-813.	13.7	984
82	Mutation ofFOXL2in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine, 2009, 360, 2719-2729.	13.9	706
83	Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy. Breast Cancer Research, 2009, 11, R87.	2.2	29
84	Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 589-598.	1.4	19
85	Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. Modern Pathology, 2008, 21, 1413-1420.	2.9	3
86	A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nature Medicine, 2008, 14, 1384-1389.	15.2	298
87	Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer, 2007, 7, 55.	1.1	341
88	A novel myoepithelial/progenitor cell marker in the breast?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 607-609.	1.4	49
89	NOVEL IMMUNOHISTOCHEMICAL MARKERS FOR THE DIFFERENTIATION OF LOBULAR AND DUCTAL INVASIVE BREAST CARCINOMAS. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2007, 151, 59-64.	0.2	34
90	Wnt Signaling Pathway in Mammary Gland Development and Carcinogenesis. Pathobiology, 2006, 73, 213-223.	1.9	175

#	Article	IF	Citations
91	DIFFERENTIATION OF TUMOURS OF DUCTAL AND LOBULAR ORIGIN: I. PROTEOMICS OF INVASIVE DUCTAL AND LOBULAR BREAST CARCINOMAS. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2005, 149, 57-62.	0.2	22
92	Differentiation of tumours of ductal and lobular origin: II. Proteomics of invasive ductal and lobular breast carcinomas. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2005, 149, 63-68.	0.2	16